Published in Pharmaceuticals (Basel) on March 30, 2010
The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respir Res (2017) 0.75
Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis. Respir Res (2017) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Chemical structure and sympathomimetic action of amines. J Physiol (1910) 32.80
G proteins: transducers of receptor-generated signals. Annu Rev Biochem (1987) 27.41
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol (2007) 15.45
Observations on recent increase in mortality from asthma. Br Med J (1968) 14.82
Differentiation of receptor systems activated by sympathomimetic amines. Nature (1967) 11.46
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med (1992) 8.53
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
Mortality from asthma: a new epidemic in New Zealand. Br Med J (Clin Res Ed) (1982) 6.78
Investigation into use of drugs preceding death from asthma. Br Med J (1968) 6.76
Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A (1981) 6.73
Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths). Br J Pharmacol (1971) 6.11
Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet (1989) 5.82
Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem (1991) 5.70
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med (2007) 5.31
G protein pathways. Science (2002) 5.29
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (2004) 5.01
beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science (1990) 4.53
Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med (2004) 4.37
Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma? Lancet (1981) 4.28
Molecular characterization of the human beta 3-adrenergic receptor. Science (1989) 4.13
Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J (1990) 4.05
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med (1996) 4.03
Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med (1998) 3.45
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med (2000) 3.08
Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax (1990) 3.02
Neural control of human airways in health and disease. Am Rev Respir Dis (1986) 2.97
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med (1996) 2.89
Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet (1995) 2.79
Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A (2009) 2.76
Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol (1985) 2.76
Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ (1993) 2.70
Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest (2003) 2.69
Asthma in New Zealand. Br Med J (Clin Res Ed) (1983) 2.63
Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med (1992) 2.52
Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax (1988) 2.40
Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol (2007) 2.24
Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol (1987) 2.24
A study of the adrenotropic receptors. Am J Physiol (1948) 2.19
Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet (1995) 2.17
Beta-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. J Biol Chem (1993) 2.13
Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax (2000) 2.10
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med (1992) 2.10
Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). Proc Natl Acad Sci U S A (1987) 2.08
Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis (1985) 1.89
Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest (2003) 1.87
Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med (1994) 1.86
Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A (2004) 1.85
Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol (1990) 1.80
Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol (2007) 1.80
Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis (1984) 1.78
A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol (2007) 1.71
Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med (2007) 1.70
COPD: current therapeutic interventions and future approaches. Eur Respir J (2005) 1.61
Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol (2009) 1.61
The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther (2007) 1.61
Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax (1993) 1.53
Beta(2)-agonists block tussive responses in guinea pigs via an atypical cAMP-dependent pathway. Eur Respir J (2009) 1.49
Beta-adrenoceptor stimulation inhibits histamine-stimulated inositol phospholipid hydrolysis in bovine tracheal smooth muscle. Br J Pharmacol (1988) 1.48
Two distinct pathways for cAMP-mediated down-regulation of the beta 2-adrenergic receptor. Phosphorylation of the receptor and regulation of its mRNA level. J Biol Chem (1989) 1.45
Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax (2002) 1.44
Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest (2005) 1.44
Purification and characterization of the beta-adrenergic receptor kinase. J Biol Chem (1987) 1.43
In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther (2006) 1.42
Scientific rationale for using a single inhaler for asthma control. Eur Respir J (2007) 1.41
Life-threatening asthma during treatment with salmeterol. N Engl J Med (2006) 1.40
Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends Pharmacol Sci (1990) 1.38
A randomised, placebo controlled trial of inhaled salbutamol and beclomethasone for recurrent cough. Arch Dis Child (1998) 1.35
ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med (2008) 1.34
Modulation of neurotransmission in airways. Physiol Rev (1992) 1.34
Role of potassium channels in bronchodilator responses in human airways. Am Rev Respir Dis (1992) 1.33
Beta-adrenergic bronchodilators. N Engl J Med (1995) 1.27
Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev (2006) 1.27
Selective inhibition of relaxation of guinea-pig trachea by charybdotoxin, a potent Ca(++)-activated K+ channel inhibitor. J Pharmacol Exp Ther (1990) 1.27
Agonist-induced destabilization of beta-adrenergic receptor mRNA. Attenuation of glucocorticoid-induced up-regulation of beta-adrenergic receptors. J Biol Chem (1989) 1.26
Bronchodilator treatment and deaths from asthma: case-control study. BMJ (2004) 1.24
Inhibition of cholinergic neurotransmission in human airways by beta 2-adrenoceptors. J Appl Physiol (1985) (1988) 1.21
Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis (1989) 1.20
cAMP stimulates transcription of the beta 2-adrenergic receptor gene in response to short-term agonist exposure. Proc Natl Acad Sci U S A (1989) 1.20
Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. J Allergy Clin Immunol (2005) 1.15
A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. Pharmacogenet Genomics (2008) 1.15
Implications of genetic variability of human beta 2-adrenergic receptor structure. Pulm Pharmacol (1995) 1.13
Synthetic functions of airway smooth muscle in asthma. Trends Pharmacol Sci (1997) 1.12
Involvement of tyrosine residues located in the carboxyl tail of the human beta 2-adrenergic receptor in agonist-induced down-regulation of the receptor. Proc Natl Acad Sci U S A (1990) 1.12
Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J (1991) 1.12
Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. Proc Natl Acad Sci U S A (1992) 1.11
Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J (2008) 1.11
Functional antagonism in canine tracheal smooth muscle: inhibition by methacholine of the mechanical and biochemical responses to isoproterenol. J Pharmacol Exp Ther (1983) 1.10
Inhibitory effect of methacholine on drug-induced relaxation, cyclic AMP accumulation, and cyclic AMP-dependent protein kinase activation in canine tracheal smooth muscle. J Pharmacol Exp Ther (1985) 1.07
Genetics of beta 2-adrenergic receptor variants in asthma. Clin Exp Allergy (1995) 1.07
Muscarinic receptor subtypes in airways. Life Sci (1993) 1.07
Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther (2007) 1.06
Targeted transgenesis reveals discrete attenuator functions of GRK and PKA in airway beta2-adrenergic receptor physiologic signaling. Proc Natl Acad Sci U S A (2009) 1.05